Infinity to Present at the 7th Annual Truist Securities Life Sciences Summit
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) is a clinical-stage biotechnology firm focused on developing eganelisib, a groundbreaking oral immuno-oncology therapy targeting immune suppression in cancer. The company announced participation in a fireside chat at the 7th Annual Truist Securities Life Sciences Summit on May 4-5, 2021, at 10:30 am ET. Investors can access the presentation via a webcast available on Infinity's website for 30 days post-event. Infinity continues to explore eganelisib in several clinical studies, including combinations with drugs like Opdivo and Tecentriq.
- None.
- None.
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which addresses a fundamental biologic mechanism of immune suppression in cancer, today announced that management will participate in a fireside chat at the 7th Annual Truist Securities Life Sciences Summit which is being held virtually Tuesday, May 4th – Wednesday, May 5th, 2021.
Presentation details are as follow:
Truist Securities Life Sciences Summit:
Date: |
Tuesday, May 4 |
|
Time: |
10:30 am Eastern Time |
|
Webcast: |
https://kvgo.com/life-sciences-summit/infinity-pharmaceuticals-may-2021 |
The webcast of the presentation can be accessed in the Investors/Media section of Infinity's website at www.infi.com and will be available on Infinity's website for 30 days following the event.
About Infinity and Eganelisib
Infinity Pharmaceuticals, Inc. (“Infinity” or the “Company”), is a clinical-stage biotechnology company developing eganelisib (IPI-549), a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which addresses a fundamental biologic mechanism of immune suppression in cancer in multiple clinical studies. MARIO-275 is a randomized, controlled combination study of eganelisib combined with Opdivo® in I/O naïve urothelial cancer. MARIO-3 is the first eganelisib combination study in front-line advanced cancer patients and is evaluating eganelisib in combination with Tecentriq® and Abraxane® in front-line TNBC and in combination with Tecentriq and Avastin® in front-line RCC. In collaboration with Arcus Biosciences, Infinity is evaluating a checkpoint inhibitor-free, novel combination regimen of eganelisib plus etrumadenant (AB928, a dual adenosine receptor antagonist) plus Doxil® in advanced TNBC patients. In 2019, Infinity completed enrollment in MARIO-1, a Phase 1/1b study evaluating eganelisib as a monotherapy and in combination with Opdivo (nivolumab) in patients with advanced solid tumors including patients refractory to checkpoint inhibitor therapy. With these studies Infinity is evaluating eganelisib in the anti-PD-1 refractory, I/O-naïve, and front-line settings. For more information on Infinity, please refer to Infinity's website at www.infi.com.
Opdivo® is a registered trademark of Bristol Myers Squibb.
Tecentriq® is a registered trademark of Genentech, Inc.
Abraxane® is a registered trademark of Abraxis BioScience, LLC., a wholly owned subsidiary of Bristol Myers Squibb Company.
Avastin® is a registered trademark of Genentech, Inc.
Doxil® is a registered trademark of Baxter Healthcare Corporation.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210427005597/en/
FAQ
When is Infinity Pharmaceuticals participating in the Truist Securities Life Sciences Summit?
How can I access the Infinity Pharmaceuticals presentation from the Life Sciences Summit?
What is eganelisib developed by Infinity Pharmaceuticals?
What clinical studies is Infinity Pharmaceuticals conducting with eganelisib?
What is the stock symbol for Infinity Pharmaceuticals?
